June 2021—Bio-Techne Corp. has reached an agreement to acquire Asuragen for initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones.
Asuragen’s portfolio of molecular diagnostic and research products include its FDA-cleared AmplideX Fragile X Diagnostic and Carrier Screening kit for the screening of prospective parents as potential carriers of Fragile X chromosomal abnormalities and its Quantitidex qPCR IS BCR-ABL kit to enable the monitoring of leukemia patients for minimal residual disease.
Asuragen CEO, Matt McManus, will join the Bio-Techne team to continue to lead the legacy Asuragen business as well as the integration process. Bio-Techne anticipates the acquisition to close in the fourth quarter of its fiscal 2021.
Bio-Techne, 612-379-2956
Asuragen, 512-681-5200